UAE firm Globalpharma has announced a partnership agreement with the Mackenzie & Stuart Group, designed to help it identify exciting new technologies suitable for the Middle East pharmaceutical market.

This agreement allows the group to act on behalf of Globalpharma for the outsourcing of ownership rights (product licences) to help develop Globalpharma’s brands.
The acquisition of product licences will allow the pharmaceutical company to manufacture and market specific products in the Middle East and GCC states.
Mackenzie & Stuart, a Europe-based consulting group, was established to facilitate trade between the Middle East and international groups. Its activities focus on brands in various sectors including the pharmaceutical industry, the food and beverage market, boating and machinery.
Paolo Cappellini, its chief executive officer, said the group had recently increased its focus on the branded pharmaceutical market to support the activities of Globalpharma. The relationship with   Globalpharma, demonstrated its first success with the UAE firm recently signing an agreement with Tiverton Laboratories, a member of the Alinter group, to manufacture and market Tiverton pharmaceuticals.”
Khalid bin Kalban, managing director and chief executive officer of Dubai Investments and chairman of Globalpharma, says:  “Globalpharma is delighted to have signed this agreement with the Mackenzie & Stuart Group. We hope that this will further consolidate our position as a leading pharmaceutical manufacturer.”
Dr Maged Amer, acting general manager, Globalpharma, said: “This agreement will facilitate the sourcing of important new products to further increase our portfolio of pharmaceutical products in the Middle East and GCC countries. We will work with the Mackenzie & Stuart Group to strengthen our position in the market and in preparation for entering the European pharmaceutical market.”